Vimarsana
Biggest News Aggregation in the World

Page 40 - Rapid Acceleration News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rapid Acceleration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rapid Acceleration Today - Breaking & Trending Today

Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021 - Vimarsana News

Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021

Message : Required fields CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 million, up 49% year-over-year Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year Diagnostics segment net revenues decreased 9% year-over-year to $31.9 million, up 5% from the first quarter of fiscal 2021 Signed agreement for 2nd grant from the National Institut...

Marc Stapley Assumes Role of Executive Chairman of the Board of Directors of Helix; President and Co-founder James Lu Appointed President and Chief Executive Officer - Vimarsana News

Marc Stapley Assumes Role of Executive Chairman of the Board of Directors of Helix; President and Co-founder James Lu Appointed President and Chief Executive Officer

Share this article Share this article SAN MATEO, Calif., May 6, 2021 /PRNewswire/ -- Helix today announced that Marc Stapley, chairman and chief executive officer, will assume the role of executive chairman of the Helix Board of Directors on June 1, 2021 and James Lu, president and co-founder, will be appointed president and chief executive officer, and join the Helix Board of Directors, on the same date.  James Lu will be appointed president and chief executive officer of Helix, effective June 1, 2021. James Lu will be appointed president and chief executive officer of Helix, effective Ju...

Northwestern spinoff receives $21.3M from NIH to manufacture COVID-19 test - Vimarsana News

Northwestern spinoff receives $21.3M from NIH to manufacture COVID-19 test

Northwestern spinoff receives $21.3M from NIH to manufacture COVID-19 test Highly sensitive PCR test takes 15 minutes, using cereal box-sized device A user inserts a small cartridge, holding a nasal swab sample, into a DASH system. A new, highly sensitive, easy-to-use test for COVID-19 that requires a single swab and 15 minutes has received $21.3 million from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx SM) initiative. Developed at Northwestern University’s Center for Innovation in Global Health Technologies (CIGHT), the point-of-care technology is being...

Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort - Vimarsana News

Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort

Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort Share: Insights, lessons learned after a year of transforming COVID-19 testing—a special journal issue One-year into implementation of the National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) initiative, the Institute of Electrical and Electronics Engineers (IEEE) Open Journal of Engineering in Medicine and Biology has dedicated a special April 29...

Source: nih.gov
Xtrava Health Receives NIH Funding for Their SPERA™ COVID-19 Ag Test - Vimarsana News

Xtrava Health Receives NIH Funding for Their SPERA™ COVID-19 Ag Test

Share this article Share this article SANTA CLARA, Calif., April 28, 2021 /PRNewswire/ -- Xtrava Health, a health technology company, today announced it has been awarded a $6.2 million contract by the National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADx SM) initiative to expedite the launch of its SPERA™ COVID-19 antigen test. Xtrava Health is one of the companies selected from a pool of more than 700 RADx applicants for the scale-up phase of the initiative. This contract follows months of meeting milestones and vetting Xtrava Health's technology and scale-...